Results 201 to 210 of about 170,290 (313)

Endovascular treatment for posterior epistaxis: should it still be considered a last-resort option? A literature review. [PDF]

open access: yesFront Surg
Martinez HR   +11 more
europepmc   +1 more source

Degradomics for large‐scale mechanistic insights on proteases and proteolysis in human health

open access: yesThe FEBS Journal, EarlyView.
Proteolysis has an important role in human disease but remains relatively unexplored. Degradomics, the uncovering of proteolysis in tissues, cells, and proteins, uses mass spectrometry‐based terminomics to identify protein termini occurring therein (forward degradomics) and to define the actions of proteases (reverse degradomics).
Daniel R. Martin   +2 more
wiley   +1 more source

A New Experimental Model of ARDS and Pulmonary Hypertension in the Dog [PDF]

open access: yes, 1989
Forst, Helmuth   +3 more
core   +1 more source

Imaging and physiology across the high–low cerebrospinal fluid pressure spectrum: Navigating diagnostic uncertainty in headache practice

open access: yesHeadache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective This study was conducted to provide a clinically oriented, mechanism‐based framework for interpreting neuroimaging across disorders of cerebrospinal fluid (CSF) pressure, with particular emphasis on patients who fall between classic diagnostic categories of spontaneous intracranial hypotension (SIH) and idiopathic intracranial ...
Andrew L. Callen, Kyle Jenkins
wiley   +1 more source

Efficacy and Safety of Second‐Line Lenvatinib After First‐Line Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma

open access: yesHepatology Research, EarlyView.
ABSTRACT Background There is a paucity of data regarding the efficacy and safety of lenvatinib as a second‐line treatment following first‐line combination immunotherapy with durvalumab and tremelimumab (Dur + Tre). Methods This retrospective multicenter study included 14 patients with unresectable hepatocellular carcinoma who received lenvatinib after ...
Ryoichi Miura   +21 more
wiley   +1 more source

Home - About - Disclaimer - Privacy